Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1550799 | 1.00 | GPR119 (0.46) | GPR119TBK1IKBKEUSP30JAK2 | |
| SCHEMBL14237609 | 0.90 | GPR119 (0.40) | GPR119TBK1JAK2KDM1A | |
| SCHEMBL2335893 | 0.89 | GPR119 (0.50) | GPR119TBK1 | |
| SCHEMBL460095 | 0.80 | GPR119 (0.49) | GPR119TBK1JAK2JAK1 | |
| SCHEMBL1550695 | 0.79 | GPR119 (0.51) | GPR119KDM1A | |
| SCHEMBL12234573 | 0.79 | GPR119 (0.51) | GPR119KDM1A | |
| SCHEMBL2541769 | 0.79 | GPR119 (0.51) | GPR119KDM1A | |
| SCHEMBL2545449 | 0.79 | GPR119 (0.51) | GPR119KDM1A | |
| SCHEMBL2545446 | 0.79 | GPR119 (0.51) | GPR119KDM1A | |
| SCHEMBL2541768 | 0.79 | GPR119 (0.51) | GPR119KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8372837-B2 | Pyridone and pyridazone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372837-B2 | Pyridone and pyridazone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372837-B2 | Pyridone and pyridazone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2313395-B1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2313395-B1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2313395-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | Bristol-Myers Squibb Company (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010009183-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010009183-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | GPR119 1/4885TBK1 2224/4885IKBKE 4242/4885 |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | GPR119 1/4885TBK1 2191/4885IKBKE 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.